James Turnbull

James Turnbull

Auto-generated profile, based on publicly available information

James Turnbull

IQVIA, New York, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
HOHolly K. K. O’Donnell
Holly K. K. O’Donnell
KSKimber M. Simmons
Kimber M. Simmons
SGStephen E. Gitelman
Stephen E. Gitelman
TDTerry Dex
Terry Dex
RHRobert Hill
Robert Hill
KHKorey K. Hood
Korey K. Hood
Aims: This study surveyed individuals and caregivers of children who received teplizumab at stage 2 type 1 diabetes (T1D) to garner real‐world experiences and their health outlook for the future following treatment with the first approved disease‐modifying immune therapy for delaying the onset of Stage 3 T1D. Materials and Methods: This was a cross‐sectional, observational, online survey (conducted September–October 2024) of adults (≥18 years) and caregivers of children (8–17 years) who received teplizumab while participating in the US COMPASS patient support program. Questions pertained to demographics, health history, T1D screening, the decision to take teplizumab, treatment, post‐treatment experience, outlook on prognosis and self‐reported health status. All data were summarized using descriptive statistics. Results: A total of 47/116 invited individuals responded (30 adults, 17 caregivers of children). Almost half of respondents had a family history of T1D, and 36% reported autoimmune comorbidities. The top reason for both screening for T1D and receiving teplizumab was for a chance at delaying Stage 3 T1D. Although respondents expressed continued concern over diabetes progression, 87% felt grateful to receive teplizumab, 72% felt it would help slow down the disease, 60% felt it would make T1D easier to manage and most (>80%) would recommend treatment/make the same decision for another family member. Conclusions: Individuals living with or caring for someone who received teplizumab felt grateful for the opportunity to delay disease or make it easier to manage following teplizumab, with most agreeing they would recommend teplizumab and make the same decision for family in their situation. Plain Language Summary: Type 1 diabetes (T1D) happens when the body destroys cells in the pancreas that make insulin. This ultimately causes high blood sugar. People with T1D often worry about the long‐term effects of the disease. Teplizumab is the first FDA‐approved treatment that delays the onset of high blood sugar in people in the early stages of T1D—when there are signs of cell damage and mild increases in blood sugar. We surveyed adults ( N = 30) and caregivers ( N = 17) of children treated with teplizumab about their journey before and after treatment. More than half of adults were initially told they might have a different type of diabetes, usually type 2, before being accurately diagnosed with early‐stage T1D. Doctors specializing in diabetes were most often the ones who recommended screening for T1D. The most common reason to screen was a chance for more time before the onset of high blood sugar. Greater than 80% of people were grateful they or their child had the opportunity to receive teplizumab, and most would recommend it to others in a similar situation. After receiving teplizumab, most people still worried about their blood sugar and measured it frequently. Most thought that teplizumab would delay the disease progression to symptoms, and more than half thought teplizumab would make T1D easier to manage. These findings are the first to describe the journey of adults and caregivers of children treated with teplizumab, their reasons for screening, and their beliefs about the future.

13 April 2025 in Oncology and Therapy
Verified
Journal Article
Open access
PDF file
MCMichael R. Chladek
Michael R. Chladek
MMMaria Virginia Meza
Maria Virginia Meza
JWJessie Wang
Jessie Wang
MSMaria D Sae-Hau
Maria D Sae-Hau
ABAna Buenfil
Ana Buenfil
NDNicolas Despiegel
Nicolas Despiegel
Introduction Treatment outcomes for older adults with B cell acute lymphoblastic leukemia (B cell ALL) are poor, partially because of poor tolerance to intense chemotherapy. Information on patient experience—an important consideration in drug development—is lacking. We investigated the signs, symptoms, and impacts of B cell ALL on older patients (or those with comorbidities that may reduce chemotherapy tolerance). Methods This observational study involved teleconference-based, qualitative, semi-structured interviews with patients newly diagnosed with B cell ALL, aged ≥ 55 years, or 30–54 years with ≥ 1 comorbidity. Participants described their B cell ALL experience, including signs, symptoms, and impacts, and how bothersome/disturbing these were from 0 (not at all) to 10 (greatly) at three timepoints (around diagnosis, at worst, and at interview). Salient signs/symptoms were those reported by ≥ 40%, with average disturbance ratings of ≥ 4. A conceptual model of key disease- and treatment-related signs, symptoms, and impacts was developed. Results Interviews with 20 participants (mean age 57.9 years; 80% diagnosed within 18 months) revealed 63 signs/symptoms and 37 impacts. All reported fatigue-related symptoms, and most reported gastrointestinal (n = 18, 90%), central/peripheral nervous system (n = 16, 80%), and pain-, respiratory-, blood-, and mouth-related (all n = 14, 70%) symptoms. Eight signs/symptoms were salient around diagnosis (fatigue, tiredness, weakness, exhaustion, shortness of breath, sweating, general pain, and diarrhea) and 16 were salient “at worst”; four remained salient at interview (all fatigue-related). All participants reported emotional impacts, and most reported physical and social impacts (both n = 16, 80%). The most frequent impact was inability to do previous hobbies/activities (n = 15, 75%), followed by decreased ability for activities of daily living and worry/fear/nervousness (both n = 12, 60%). Conclusion This study provides insight into patients’ experience with newly diagnosed B cell ALL among older patients or those with clinically significant comorbidities. This enhances understanding of what matters most to patients and informs future treatment development and clinical care.

10 July 2026 in EJC Skin Cancer
Verified
Journal Article
Open access
SMShehan McFadden
Shehan McFadden
SPSwaha Pattanaik
Swaha Pattanaik
JBJoanne Buzaglo
Joanne Buzaglo
JTJames Turnbull
James Turnbull
ABAdyb Baakili
Adyb Baakili
STSophie Van Tomme
Sophie Van Tomme

1 April 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
SMShehan McFadden
Shehan McFadden
SPSwaha Pattanaik
Swaha Pattanaik
JBJoanne Buzaglo
Joanne Buzaglo
JTJames Turnbull
James Turnbull
ABAdyb Baakili
Adyb Baakili
STSophie Van Tomme
Sophie Van Tomme
Background: Patients with advanced/metastatic melanoma experience various symptoms that significantly impact on their health-related quality of life (HRQoL). However, a comprehensive conceptual model (CM) has not been developed to capture the full spectrum of patient-reported symptoms and impacts. This study aimed to develop a patient-centered CM for advanced/metastatic melanoma.Methods: Targeted literature review and clinician interviews informed the development of a preliminary CM. To refine and finalize the CM, semi-structured interviews were conducted with US-based patients diagnosed with advanced or metastatic melanoma. Furthermore, the Functional Assessment of Cancer Therapy-Melanoma (FACT-M), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), pain Numeric Rating Scale (NRS), and itch NRS were chosen for cognitive debriefing of patients.Results: The preliminary CM was developed using 10 articles and five patient blogs. Interviews with three clinicians identified 15 priority symptoms and one key impact. Subsequently, interviews with 20 patients revealed additional 70 symptoms and 47 impacts. Frequently reported and bothersome symptoms included fatigue (n=19), lumps or nodes (n=14), fever (n=13), joint pain (n=13), changes in vision (n=13), chills (n=12), and itching (n=11). Debriefing of FACT-M, EORTC QLQ-C30, pain NRS, and itch NRS items revealed that most participants found these measures clear, easy to understand, and relevant to their experiences with advanced/metastatic melanoma.Conclusions: This study presents the first patient-informed CM for advanced/metastatic melanoma, offering a comprehensive overview of the disease- and treatment-related symptoms and impacts, which can guide the selection of meaningful outcome measures in future clinical trials.